Funding accelerates advancement of AngioAI+, the company’s investigational AI-based platform for diagnosing CAD and CMD.

MINNETONKA, Minn.--(BUSINESS WIRE)--

AngioInsight, a leader in AI-powered cardiovascular diagnostics, today announced the appointment of Shlomi Nachman, former Worldwide Chairman of Johnson & Johnson’s Cardiovascular and Specialty Solutions (CSS), to its Board of Directors. AngioInsight is further announcing initiation of its Series A round of $25M, following the successful closing of its oversubscribed seed funding round. The investment will support the ongoing development of AngioAI+™, the company’s software only based platform being designed to improve diagnostic accuracy for coronary artery disease (CAD) and to provide detection of coronary microvascular disease (CMD) in real time.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251023754425/en/

Nachman brings more than 25 years of cardiovascular global medtech leadership to AngioInsight’s Board. At Johnson & Johnson, he oversaw $9 billion of annual revenue where he led groundbreaking cardiovascular innovations and played a key role in scaling complex healthcare solutions worldwide. His deep strategic insight will support AngioInsight’s next phase of development of the AI-driven angiographic assessment platform.

“We are honored to welcome Shlomi to our Board at this pivotal time," said Scott Burger, CEO of AngioInsight. "His vision and proven ability to lead innovation in cardiovascular care align perfectly with our mission to bring advanced, real-time AI insights to interventional cardiologists—improving diagnosis and outcomes for millions of patients."

The Series A funding will support the clinical evaluation and commercial launch of AngioAI+, AngioInsight’s proprietary platform that aids in assessing coronary physiology—including key diagnostic metrics such as Fractional Flow Reserve (FFR) and Coronary Flow Reserve (CFR) for the detection of CAD and CMD directly from angiographic images. Without the need for invasive pressure wires, hyperemic agents, or additional procedural steps, AngioAI+ is being designed to provide real-time diagnostic insights within minutes.

“AngioInsight’s technology represents a transformative shift in how cardiovascular disease will be diagnosed and treated,” said Shlomi Nachman. “I’m excited to partner with this team to help bring their groundbreaking platform to market and advance the next frontier of precision cardiology.”

With over 20 million1 Americans affected by CAD and increasing attention to underdiagnosed conditions such as CMD—particularly in women—AngioInsight is poised to play a central role in the evolution of AI-guided diagnostic cardiac care.

About AngioInsight, Inc.

AngioInsight is developing next-generation AI solutions to transform how cardiovascular disease is diagnosed and managed. Its proprietary software platform is being designed to provide real-time, image-based insights for both anatomical and functional coronary assessment—including the detection of coronary microvascular disease, often missed or misdiagnosed, especially in women. AngioInsight’s mission is to enable more accurate, efficient, and accessible cardiovascular care for providers and their patients.

About AngioAI+™

AngioAI+ is AngioInsight’s software-only based platform being designed to integrate into current clinical workflows to support physicians with rapid, AI-powered angiographic interpretation and disease detection. Its algorithms are designed to analyze angiographic images to provide assessment of coronary artery disease and coronary microvascular disease; supporting more informed decisions during interventional procedures.

CAUTION: Investigational device. Limited by Federal (or United States) law to investigational use.

National Institutes of Health. Heart Disease and Stroke Statistics—2023 Update. Circulation 147, no. 8 (2023). https://doi.org/10.1161/CIR.0000000000001123.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251023754425/en/

Source: AngioInsight